U.S. Markets closed
  • S&P Futures

    3,608.00
    +6.50 (+0.18%)
     
  • Dow Futures

    28,893.00
    +92.00 (+0.32%)
     
  • Nasdaq Futures

    11,021.25
    -14.25 (-0.13%)
     
  • Russell 2000 Futures

    1,675.00
    +5.20 (+0.31%)
     
  • Crude Oil

    82.05
    +2.56 (+3.22%)
     
  • Gold

    1,672.10
    +0.10 (+0.01%)
     
  • Silver

    19.11
    +0.07 (+0.37%)
     
  • EUR/USD

    0.9804
    -0.0015 (-0.1569%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1157
    +0.0034 (+0.3046%)
     
  • USD/JPY

    144.7300
    +0.2870 (+0.1987%)
     
  • BTC-USD

    19,207.41
    -116.42 (-0.60%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.89 (-1.84%)
     

Addus HomeCare Corporation Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next

·4 min read

Addus HomeCare Corporation (NASDAQ:ADUS) came out with its second-quarter results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. Revenues were in line with forecasts, at US$237m, although statutory earnings per share came in 12% below what the analysts expected, at US$0.70 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Check out our latest analysis for Addus HomeCare

earnings-and-revenue-growth
earnings-and-revenue-growth

Taking into account the latest results, the current consensus from Addus HomeCare's nine analysts is for revenues of US$960.1m in 2022, which would reflect a reasonable 6.1% increase on its sales over the past 12 months. Statutory earnings per share are predicted to swell 13% to US$3.15. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$955.5m and earnings per share (EPS) of US$3.17 in 2022. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$112. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Addus HomeCare analyst has a price target of US$135 per share, while the most pessimistic values it at US$95.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Addus HomeCare's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Addus HomeCare's revenue growth will slow down substantially, with revenues to the end of 2022 expected to display 13% growth on an annualised basis. This is compared to a historical growth rate of 17% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 7.1% per year. Even after the forecast slowdown in growth, it seems obvious that Addus HomeCare is also expected to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Addus HomeCare going out to 2024, and you can see them free on our platform here..

And what about risks? Every company has them, and we've spotted 1 warning sign for Addus HomeCare you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here